Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

Deborah Grayson, a top pharmacist and nutritional therapist, has warned that weight loss medication can cause an inflamed ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Weight fluctuation was associated with a greater risk for diabetic kidney disease progression among individuals with type 1 diabetes.

The prevalence of obesity and diabetes has grown worldwide, presenting notable challenges to public health and health care ...